Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Schad, Friedemann [VerfasserIn]   i
 Thronicke, Anja [VerfasserIn]   i
 Hofheinz, Ralf-Dieter [VerfasserIn]   i
 Matthes, Harald [VerfasserIn]   i
 Grah, Christian [VerfasserIn]   i
Titel:Patients with advanced or metastasised non-small-cell lung cancer with Viscum album L. therapy in addition to PD-1/PD-L1 blockade
Titelzusatz:a real-world data study
Verf.angabe:Friedemann Schad, Anja Thronicke, Ralf-Dieter Hofheinz, Harald Matthes and Christian Grah
E-Jahr:2024
Jahr:22 April 2024
Umfang:19 S.
Fussnoten:Gesehen am 03.02.2025
Weitere Titel:Dieser Artikel gehört zum Special issue: Immune checkpoint inhibitors, targeted therapies and adjuvant treatment of lung cancer
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2024
Band/Heft Quelle:16(2024), 8, Artikel-ID 1609, Seite 1-19
ISSN Quelle:2072-6694
Abstract:Immunotherapy with PD-1/PD-L1 inhibitors has significantly improved the survival rates of patients with metastatic non-small-cell lung cancer (NSCLC). Results of a real-world data study investigating add-on VA (Viscum album L.) to chemotherapy have shown an association with the improved overall survival of patients with NSCLC. We sought to investigate whether the addition of VA to PD-1/PD-L1 inhibitors in patients with advanced or metastasised NSCLC would have an additional survival benefit. In the present real-world data study, we enrolled patients from the accredited national registry, Network Oncology, with advanced or metastasised NSCLC. The reporting of data was performed in accordance with the ESMO-GROW criteria for the optimal reporting of oncological real-world evidence (RWE) studies. Overall survival was compared between patients receiving PD-1/PD-L1 inhibitor therapy (control, CTRL group) versus the combination of anti-PD-1/PD-L1 therapy and VA (combination, COMB group). An adjusted multivariate Cox proportional hazard analysis was performed to investigate variables associated with survival. From 31 July 2015 to 9 May 2023, 415 patients with a median age of 68 years and a male/female ratio of 1.2 were treated with anti-PD-1/PD-L1 therapy with or without add-on VA. Survival analyses included 222 (53.5%) patients within the CRTL group and 193 (46.5%) in the COMB group. Patients in the COMB group revealed a median survival of 13.8 months and patients in the CRTL group a median survival of 6.8 months (adjusted hazard ratio, aHR: 0.60, 95% CI: 0.43-0.85, p = 0.004) after adjustment for age, gender, tumour stage, BMI, ECOG status, oncological treatment, and PD-L1 tumour proportion score. A reduction in the adjusted hazard of death by 56% was seen with the addition of VA (aHR 0.44, 95% CI: 0.26-0.74, p = 0.002) in patients with PD-L1-positive tumours (tumour proportion score > 1%) treated with first-line anti-PD-1/PD-L1 therapy. Our findings suggest that add-on VA correlates with improved survival in patients with advanced or metastasised NSCLC who were treated with PD-1/PD-L1 inhibitors irrespective of age, gender, tumour stage, or oncological treatment. The underlying mechanisms may include the synergistic modulation of the immune response. A limitation of this study is the observational non-randomised study design, which only allows limited conclusions to be drawn and prospective randomised trials are warranted.
DOI:doi:10.3390/cancers16081609
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.3390/cancers16081609
 kostenfrei: Volltext: https://www.mdpi.com/2072-6694/16/8/1609
 DOI: https://doi.org/10.3390/cancers16081609
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:<i>Viscum album</i> L. extracts
 lung cancer
 non-small-cell lung cancer
 PD-1 inhibitor
 PD-L1 inhibitor
 real-world data study
 survival
K10plus-PPN:1916169139
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69297128   QR-Code
zum Seitenanfang